Results of treatment for male prolactinomas

被引:0
|
作者
Iwai, Y [1 ]
Yamanaka, K [1 ]
Ishiguro, T [1 ]
Morikawa, T [1 ]
Matsuzaka, Y [1 ]
Komiyama, M [1 ]
Yasui, T [1 ]
机构
[1] Osaka City Gen Hosp, Dept Neurosurg, Miyakojima Ku, Osaka 5340021, Japan
来源
NEUROLOGICAL SURGERY | 2002年 / 30卷 / 12期
关键词
prolactinoma; male; bromocriptine; dopamine agonist; pituitary gland;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We evaluated the results of medical treatment for male prolactinomas. We encountered eight patients with male prolactinomas. The age was 25 to 54 years old (mean 43 years) and the chief clinical symptoms were visual acuity/field defect in three patients, pituitary apoplexy in one patient, disturbance of ejection in one patient, generalized convulsion in one patient, headache in one patient and general fatigue in one patient. The serum prolactin level was 279 to 7,360ng/ml (mean 2,832ng/ml). The tumors in all patients were large with a mean diameter of 34.9mm (range, 21 to 43mm). In only one patient, the operation was performed due to pituitary apoplexy. All the patients were treated by medication, with bromocriptine being used in seven patients and, terguride in one. The follow-up period was 0.8 to 13 years (mean 5.9 years) and, in all patients, the medical treatment was continued. The tumor decreased in size in all patients and the serum prolactin level at the last follow-up observation was 0.5 to 70.5ng/ml (mean 26.9ng/ml). All the neurological symptoms disappeared in the early stage of treatment., As for the complications of medical treatment; in one patient, orthostatic hypotension occurred during the initial administration of bromocriptine and one patient suffered CSF leakage two months after the administration of bromocriptine, so the repair of the sella floor by transsphenoidal surgery was necessary. The medical treatment for male prolactinomas is effective for a long term and should be the primary treatment for the male prolactinomas. In conclusion, patients can maintain a good quality of life for a long time by using dopamine agonists
引用
收藏
页码:1285 / 1292
页数:8
相关论文
共 50 条
  • [1] Clinical features and medical treatment of male prolactinomas
    Asano, S
    Ueki, K
    Suzuki, I
    Kirino, T
    ACTA NEUROCHIRURGICA, 2001, 143 (05) : 465 - 470
  • [2] Clinical Features and Medical Treatment of Male Prolactinomas
    S. Asano
    K. Ueki
    I. Suzuki
    T. Kirino
    Acta Neurochirurgica, 2001, 143 : 465 - 470
  • [3] Long-term follow-up results of carbergoline treatment for giant male prolactinomas
    Taguchi, Manabu
    Takeshita, Akira
    Takeuchi, Yasuhiro
    Yamada, Shozo
    Fujita, Toshiro
    ENDOCRINE JOURNAL, 2010, 57 : S508 - S509
  • [4] RESULTS OF TREATMENT OF PROLACTINOMAS WITH A NEW DOPAMINE AGONIST
    SVOBODA, T
    LUGER, A
    KNOSP, E
    GEYER, G
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1991, 116 (33) : 1224 - 1227
  • [5] Clinical features and medical treatment of male prolactinomas -: Comment
    Lüdecke, DK
    ACTA NEUROCHIRURGICA, 2001, 143 (05) : 470 - 470
  • [6] Characterization of Presentation and Treatment Patterns of Prolactinomas in Male and Female Patients
    Gupta, Arpeta
    Richter, Michael D.
    Kamal, Faisal
    Post, Kalmon D.
    Geer, Eliza B.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [7] RESULTS OF PRIMARY-TREATMENT WITH BROMOCRIPTINE OF PROLACTINOMAS WITH EXTRASELLAR EXTENSION
    VANTVERLAAT, JW
    CROUGHS, RJM
    HENDRIKS, MJ
    BOSMA, NJ
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1990, 17 (01) : 71 - 73
  • [8] Operative treatment of prolactinomas - current indications and results in 212 patients
    Kreutzer, J.
    Buslei, R.
    Wallaschofski, H.
    Nimsky, C.
    Hofmann, B.
    Fahlbusch, R.
    Buchfelder, M.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2007, 115 : S38 - S38
  • [9] Treatment of prolactinomas
    Colao, A
    Annunziato, L
    Lombardi, G
    ANNALS OF MEDICINE, 1998, 30 (05) : 452 - 459
  • [10] Effect of Chronic Cabergoline Treatment and Testosterone Replacement on Metabolism in Male Patients with Prolactinomas
    Auriemma, Renata S.
    Galdiero, Mariano
    Vitale, Pasquale
    Granieri, Luciana
    Lo Calzo, Fabio
    Salzano, Ciro
    Ferreri, Lucia
    Pivonello, Claudia
    Cariati, Federica
    Coppola, Giorgio
    de Angelis, Cristina
    Colao, Annamaria
    Pivonello, Rosario
    NEUROENDOCRINOLOGY, 2015, 101 (01) : 66 - 81